1991
DOI: 10.1016/0378-5122(91)90185-s
|View full text |Cite
|
Sign up to set email alerts
|

91203549 Ovarian cancer screening

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
3

Year Published

2012
2012
2013
2013

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(5 citation statements)
references
References 0 publications
0
2
0
3
Order By: Relevance
“…Transvaginal sonography is a much more sensitive way of detecting ovarian abnormalities but lacks specificity in distinguishing between benign and malignant lesions, 9 which may result in unnecessary surgery on patients with benign lesions or, conversely, inappropriate surgery in cases at malignant masses. 3 Ovarian carcinoma is the leading cause of death by gynecologic malignancy, mainly due to the inability to screen for the disease especially in early stages.…”
mentioning
confidence: 99%
“…Transvaginal sonography is a much more sensitive way of detecting ovarian abnormalities but lacks specificity in distinguishing between benign and malignant lesions, 9 which may result in unnecessary surgery on patients with benign lesions or, conversely, inappropriate surgery in cases at malignant masses. 3 Ovarian carcinoma is the leading cause of death by gynecologic malignancy, mainly due to the inability to screen for the disease especially in early stages.…”
mentioning
confidence: 99%
“…The ability to predict a benign process versus a malignancy preoperatively could alter many decisions in the course of management, including but not limited to surveillance vs. immediate intervention, referral to a gynecologic oncologist vs. management by a gynecologist, type of surgical approach (laparoscopy vs. laparotomy) and type of surgical incision [2,3]. Ultrasound characteristics can be used to improve discrimination between benign and malignant disease [4].…”
Section: Introductionmentioning
confidence: 99%
“…Δυστυχώς, το 80% των περιπτώσεων καρκίνου των ωοθηκών Οιαγιγνώσκονται σε προχωρημένο στάδιο. Το 20% διαγιγνώσκονται στο Ιο και 2ο στάδιο, το 70% στο 3ο στάδιο και το 10%• στο 4ο στάδιο (10).…”
Section: ι οunclassified
“…Η ύπαρξη κυστικών ή συμπαγών βλαβών στις ωοθήκες. (10,22,24,25,29,32,97,98,108), με πρωτοπόρο στον συγκεκριμένο τομέα τον S. Campell, ο οποίος καθόρισε και τα διεθνώς αποδεκτά κριτήρια σήμερα, της μορφολογίας και του όγκου των ωοθηκών που θέτουν την υποψία νεοπλασματικής νόσου των ωοθηκών. Η χρήση του διάκοιλιακού υπερηχογραφήματος ως μοναδικού screening test, ενώ έχει πολύ υψηλά ποσοστά ευαισθησίας, εμφανίζει ειδικότητα της τάξεως του 94,6% περίπου στην υπάρχουσα διεθνή βιβλιογραφία με αποτέλεσμα τα πολλά ψευδούς θετικά αποτελέσματα (77,98,108).…”
Section: γ γυναικολογική εξέτασηunclassified
See 1 more Smart Citation